Table 1 Demographics, cardiovascular risk factors, and disease-related data in RA patients
RA (n = 1279) | |
|---|---|
Age, years | 58 ± 13 |
Female, n (%) | 982 (72) |
BMI, kg/m2 | 28 ± 5 |
Abdominal circumference, cm | 94 ± 15 |
Cardiovascular data | |
CV risk factors, n (%) | |
Current smoker | 326 (25) |
Obesity | 354 (28) |
Dyslipidemia | 611 (48) |
Hypertension | 468 (37) |
Diabetes mellitus | 0 (0) |
Blood pressure, mmHg | |
Systolic | 131 ± 17 |
Diastolic | 78 ± 10 |
Lipids | |
Total cholesterol, mmol/l | 5.28 ± 0.96 |
Triglycerides, mmol/l | 1.27 ± 0.70 |
HDL cholesterol, mmol/l | 1.58 ± 0.44 |
LDL cholesterol, mmol/l | 3.10 ± 0.80 |
Atherogenic index | 3.56 ± 1.06 |
Statins, n (%) | 303 (24) |
Aspirin, n (%) | 43 (3) |
Antihypertensive treatment, n (%) | 335 (26) |
Disease-related data | |
Disease duration, years | 5 (2–12) |
CRP at time of study, mg/l | 2.7 (0.9–6.7) |
ESR at time of study, mm/1° h | 12 (5–23) |
Rheumatoid factor, n (%) | 753 (59) |
ACPA, n (%) | 682 (53) |
DAS28-ESR | 3.09 ± 1.49 |
DAS28-PCR | 2.99 ± 1.28 |
SDAI | 10 (5–18) |
CDAI | 9 (4–16) |
HAQ | 0.750 (0.250–1.250) |
RAPID | 3.15 ± 2.03 |
Current drugs, n (%) | |
Prednisone | 636 (50) |
Prednisone doses, mg/day | 5 (4–6) |
NSAIDs | 498 (39) |
DMARDs | 983 (77) |
Methotrexate | 730 (57) |
Leflunomide | 141 (11) |
Hydroxychloroquine | 282 (22) |
Sulphasalazine | 44 (3) |
Anti-TNF therapy | 166 (13) |
Adalimumab | 56 (4) |
Infliximab | 18 (1) |
Etanercept | 66 (5) |
Golimumab | 5 (0) |
Tocilizumab | 65 (5) |
Rituximab | 21 (2) |
Abatacept | 22 (2) |
Baricitinib | 12 (1) |
Tofacitinib | 14 (1) |
Historical disease-related data | |
History of extraarticular manifestations, n (%) | 232 (18) |
Erosions, n (%) | 453 (35) |
CRP at time of disease diagnosis, mg/l | 7.0 (2.0–20.0) |
CRP > 3 at time of diagnosis, n (%) | 685 (54) |
ESR at the time of disease diagnosis, mm/1° h | 21 (11.38) |
Subclinical atherosclerosis | |
Carotid IMT, μm | 690 ± 140 |
Carotid plaques, n (%) | 678 (53) |